DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ponezumab
Ponezumab
Review Article Targeting Beta Amyloid: a Clinical Review of Immunotherapeutic Approaches in Alzheimer’S Disease
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Amyloid-Beta Immunotherapy: the Hope for Alzheimer Disease?
Treatment of Alzheimer's Disease and Blood–Brain Barrier Drug Delivery
( 12 ) United States Patent
Structure of Crenezumab Complex with Aβ Shows Loss of Β-Hairpin
The Two Tontti Tudiul Lui Hi Ha Unit
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Monoclonal Antibodies As Neurological Therapeutics
(INN) for Biological and Biotechnological Substances
As of August 7, 2014
Profile of Gantenerumab and Its Potential in the Treatment of Alzheimer’S Disease
As of February 27, 2015
Development of the Clinical Candidate PBD-C06, a Humanized Pglu3-Aβ-Specific Antibody Against Alzheimer's Disease with Reduced Complement Activation
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
What Have We Learned from Aducanumab?
The Use of Monoclonal Antibodies in Treatment of Alzheimer Disease
Top View
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
(INN) for Biological and Biotechnological Substances
Bapineuzumab Alters Ab Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy
My Name Is Dr
Introduction
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Ponezumab in Mild-To-Moderate Alzheimer's Disease
Review Article Targeting Beta Amyloid: a Clinical Review of Immunotherapeutic Approaches in Alzheimer’S Disease
Anti-Amyloid-Β Monoclonal Antibodies for Alzheimer's Disease
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Immunotherapy Targeting Amyloid-Β Peptides in Alzheimer's Disease
Moving Beyond the Aβeta Hypothesis of Alzheimer's Disease
Structural and Kinetic Basis for the Selectivity of Aducanumab for Aggregated Forms of Amyloid-Β Received: 10 January 2018 Joseph W
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Bapineuzumab Captures the N-Terminus of the Alzheimer’S Disease Amyloid-Beta SUBJECT AREAS: NANOCRYSTALLOGRAPHY Peptide in a Helical Conformation
April 1, 2021 the Honorable Xavier Becerra Secretary of Health And
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
(INN) for Biological and Biotechnological Substances
WO 2018/231759 Al 20 December 2018 (20.12.2018) W !P O PCT
Clinical Application of Monoclonal Antibodies in Targeted Therapy
Redalyc.Amyloid-Beta Immunotherapy: the Hope for Alzheimer Disease?
WO 2015/038818 A2 19 March 2015 (19.03.2015) P O P C T
Profile of Gantenerumab and Its Potential in the Treatment Of
Computational Analysis for the Rational Design of Anti-Amyloid Beta (A ) Antibodies
WO 2017/189679 Al 02 November 2017 (02.11.2017) W !P O PCT